Pharmacology & Therapeutics

Article	Citations
Editorial Board	339
Inflammation, lipids, and pain in vulvar disease	336
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	300
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	270
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	252
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	225
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	221
Collateral lethality: A unique type of synthetic lethality in cancers	196
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	189
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	189
Adenosine receptor signalling as a driver of pulmonary fibrosis	180
The role of macrophages in asthma-related fibrosis and remodelling	170
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	168
Unfolded protein responses: Dynamic machinery in wound healing	145
Matrikines in the skin: Origin, effects, and therapeutic potential	144
Potential neonatal toxicity of new psychoactive substances	139
Non-canonical G protein signaling	137
Endothelial dysfunction as a complication of anti-cancer therapy	134
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	128
Contribution of non-selective membrane channels and receptors in epilepsy	127
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	126
Sleep apnea and pulmonary hypertension: A riddle waiting to be solved	125
Boron in cancer therapeutics: An overview	112
Cell-based therapies for vascular regeneration: Past, present and future	111
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	108

Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	108
TLR4 biased small molecule modulators	102
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	102
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	100
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	99
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	97
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	94
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	94
TAAR1 as an emerging target for the treatment of psychiatric disorders	92
Dysregulation of metabolic pathways in pulmonary fibrosis	92
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	90
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	90
Management of drug-resistant hypertension as a heterogeneous disorder	89
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	89
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	89
Editorial Board	87
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	86
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	85
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	83
Review: Sex-related differences in the treatment of cardiac arrhythmia	83
Bispecific antibodies for the treatment of neuroblastoma	82
PGRMC1: An enigmatic heme-binding protein	77
Natural products that alleviate depression: The putative role of autophagy	76
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	75
Pharmacological treatment of cardiogenic shock – A state of the art review	74
Wnt signaling: A prospective therapeutic target for chronic pain	74
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	73
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	73
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	72
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	72
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	70
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	70
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	69
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	66
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	65
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	64
Stabilizing the neural barrier – A novel approach in pain therapy	64
DNA methylation in cell plasticity and malignant transformation in liver diseases	64
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	63
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	62
Advances in pathogenesis and therapeutic strategies for osteoporosis	61
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	61
Optimizing drug therapies in cardiac amyloidosis	60
Neuromuscular and cardiac organoids and assembloids: Advanced platforms for drug testing	59
The role of drug-metabolizing enzymes in synthetic lethality of cancer	59
Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases	58
MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs	58
Chemical diversity, traditional uses, and bioactivities of Rosa roxburghii Tratt: A comprehensive review	57
Editorial: Beyond the opioid crisis: New targets for the management of chronic pain	57
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease	57

Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response	57
Regulation of feeding and therapeutic application of bioactive peptides	56
Therapeutic targeting of DNA methylation alterations in cancer	56
In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress	56
Recent advances in riboflavin transporter RFVT and its genetic disease	56
Drug repurposing for COVID-19: Approaches, challenges and promising candidates	54
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	53
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics	53
Extracellular vesicles in cardiovascular disease: Biological functions and therapeutic implications	53
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review	52
Editorial Board	51
Editorial Board	51
Pharmacological potential of cyclic nucleotide signaling in immunity	51
MicroRNAs in drug addiction: Current status and future perspectives	50
Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders	50
Cerebrovascular protective functions of amyloid precursor protein: Progress and therapeutic prospects	50
CDNF and ER stress: Pharmacology and therapeutic possibilities	50
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets	50
Emerging methods for and novel insights gained by absolute quantification of mitochondrial DNA copy number and its clinical applications	50
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery	49
The emerging science of Glioception: Contribution of glia in sensing, transduction, circuit integration of interoception	49
Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials	49
The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications	49
Therapeutic exploration of biased ligands at class A G protein-coupled receptors over the past 20 years	49
Organic anion transporters in remote sensing and organ crosstalk	48
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation	47
Bridging the gap: The endocannabinoid system as a functional fulcrum for benzodiazepines in a novel frontier of anxiety pharmacotherapy	47
Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: Bridging the gap of hepatic uptake clearance between in vitro and in vivo	47
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment	46
Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer	46
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination	45
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	45
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	45
Integrins in cancer: Emerging mechanisms and therapeutic opportunities	45
Editorial Board	45
Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?	44
Exploring the landscape of post-translational modification in drug discovery	44
Modulation of hyaluronan signaling as a therapeutic target in human disease	44
G protein-coupled estrogen receptor biased signaling in health and disease	44
The role and participation of immune cells in the endometrial tumor microenvironment	43
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	43
Molecular mechanisms of ferroptosis and their involvement in brain diseases	42
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	42
Resolving inflammation by TAM receptor activation	42
The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets	42
The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases	41
Editorial Board	41
Annexin A1 in neurological disorders: Neuroprotection and glial modulation	41
Understanding the molecular bridges between the drugs and immune cell	40
Targeting cell cycle checkpoints for glioma therapy	40
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	39
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	39
Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors	39
Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology	38
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	38
Platelet lipid metabolism in vascular thrombo-inflammation	38
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	38
Roles of NLRC4 inflammasome in neurological disorders: Mechanisms, implications, and therapeutic potential	37
Editorial Board	37
Early life adversities, psychopathologies and novel pharmacological strategies	37
From bench to clinic: Emerging therapies for corneal scarring	37
Modulating glucocorticoid receptor actions in physiology and pathology: Insights from coregulators	37
Potential targeting of the tumor microenvironment to improve cancer virotherapy	37
Targeting the Semaphorin3E-plexinD1 complex in allergic asthma	37
Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations	37
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets	36
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them	36
Signaling pathways in brain ischemia: Mechanisms and therapeutic implications	36
Prolactin and pain of endometriosis	35
Resolution of inflammation: An organizing principle in biology and medicine	35
Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis	35
Plant-derived nanovesicles and therapeutic application	35
The essential role of docosahexaenoic acid and its derivatives for retinal integrity	34
The antidepressant actions of ketamine and its enantiomers	34
Editorial Board	33
Editorial Board	33
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy	33
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications	32
Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease	32
Treatment of overdose in the synthetic opioid era	32

Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics	32
Gene and stem cell therapy for inherited cardiac arrhythmias	32
Anti-cancer activity of sustained release capsaicin formulations	32
Multitasking bamboo leaf-derived compounds in prevention of infectious, inflammatory, atherosclerotic, metabolic, and neuropsychiatric diseases	32
Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle	31
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?	31
Retina-directed gene therapy: Achievements and remaining challenges	31
Biased signaling in drug discovery and precision medicine	31
Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities	31
Bile acids and neurological disease	31
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics	31
Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis	31
Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections	31
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy	30
Editorial Board	30
Anticancer or carcinogenic? The role of estrogen receptor β in breast cancer progression	30
The multifaceted role of agents counteracting metabolic syndrome: A new hope for gastrointestinal cancer therapy	30
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis	30
The cardiovascular effects of air pollution: Prevention and reversal by pharmacological agents	30
Microvascular basis of cognitive impairment in type 1 diabetes	30
Lessons learned from 20 years of preclinical testing in pediatric cancers	30
Spotlight on plasticity-related genes: Current insights in health and disease	30
Resolution of inflammation in oral diseases	30
Human PSC-derived liver cells and their applications for disease models and drug discovery	30
CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases	29
Clinical advances in oncolytic virotherapy for pediatric brain tumors	29
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?	29
The free fatty acid receptor 2 (FFA2): Mechanisms of action, biased signaling, and clinical prospects	29
Mechanistic insights into medulloblastoma relapse	29
Targeting immunoproteasome in neurodegeneration: A glance to the future	29
A comprehensive review on pharmacokinetic mechanism of herb-herb/drug interactions in Chinese herbal formula	29
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance	28
“RB-reactivator screening” as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist)	28
The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy	28
Therapeutic strategies to target connective tissue growth factor in fibrotic lung diseases	28
Bile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols	28
Suppressor tRNAs as personalized therapy for nonsense mutation-associated pathologies	28
Artificial intelligence with mass spectrometry-based multimodal molecular profiling methods for advancing therapeutic discovery of infectious diseases	28
Advances in understanding cancer-associated neurogenesis and its implications on the neuroimmune axis in cancer	28
Targeting hedgehog signaling in pancreatic ductal adenocarcinoma	28
Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities	28
The future of targeted kinase inhibitors in melanoma	27
Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis	27
PPARγ signaling in hepatocarcinogenesis: Mechanistic insights for cellular reprogramming and therapeutic implications	27
From exploring cancer and virus targets to discovering active peptides through mRNA display	27
Potential application of natural compounds in ischaemic stroke: Focusing on the mechanisms underlying “lysosomocentric” dysfunction of the autophagy-lysosomal pathway	27
Antithrombotic therapy following transcatheter aortic valve intervention	27
Editorial Board	27
Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders	26
Formylpeptide receptors: A novel target to treat cardiometabolic complications	26
A natural products solution to diabetic nephropathy therapy	26
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure	26
ThermoTRP channels in pain sexual dimorphism: new insights for drug intervention	26
Sex differences in eicosanoid formation and metabolism: A possible mediator of sex discrepancies in cardiovascular diseases	26
Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications	25
Functional hydrogels as therapeutic tools for spinal cord injury: New perspectives on immunopharmacological interventions	25
Impact of drug treatment and drug interactions in post-stroke epilepsy	25
Antiviral drug repurposing: different approaches and the case of antifungal drugs	25
The pharmacodynamic and pharmacological mechanisms underlying nanovesicles of natural products: Developments and challenges	25
Editorial Board	25
Emerging roles of lysophosphatidic acid receptor subtype 5 (LPAR5) in inflammatory diseases and cancer	25
Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies	25
Editorial Board	25
The unique function of p130Cas in regulating the bone metabolism	25
The many facets of biased signaling: Mechanisms and possible therapeutic implications	24
Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma	24
CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control	24
Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies	24
Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics	24
Probiotics: Potential novel therapeutics for microbiota-gut-brain axis dysfunction across gender and lifespan	24
Retracing our steps: A review on autism research in children, its limitation and impending pharmacological interventions	23
The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans	23
The role of the STAT3 signaling transduction pathways in radioresistance	23
Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response	23
Novel strategies exploiting interleukin-12 in cancer immunotherapy	23
Bioactive lipid regulation of platelet function, hemostasis, and thrombosis	23
The complex molecular pharmacology of the dopamine D2 receptor: Implications for pramipexole, ropinirole, and rotigotine	23
Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?	23
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease	23
Editorial Board	22
Editorial Board	22
Overview of the role of purinergic signaling and insights into its role in cancer therapy	22
Targeting selective autophagy in CNS disorders by small-molecule compounds	22
Glyoxalase I is a novel target for the prevention of metabolic derangement	22
Understanding the physiological role of NaV1.9: Challenges and opportunities for pain modulation	22
Improvement of chronic metabolic inflammation and regulation of gut homeostasis: Tea as a potential therapy	22
The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?	22
Cytochrome P450-derived fatty acid epoxides and diols in angiogenesis and stem cell biology	22
Editorial Board	22
Inflammation in kidney repair: Mechanism and therapeutic potential	22
Potassium homeostasis – Physiology and pharmacology in a clinical context	21
Endothelial progenitor cells in the host defense response	21
Pulmonary vascular fibrosis in pulmonary hypertension – The role of the extracellular matrix as a therapeutic target	21
Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells	21
The gabapentinoid drugs and their abuse potential	21